scholarly journals Study of serum fucose level in breast malignancy

2019 ◽  
Vol 6 (10) ◽  
pp. 3749
Author(s):  
Ashok S. Kamble ◽  
Raj Kanthawar ◽  
N. Vijayan
Keyword(s):  
Breast Cancer ◽  
Serum Level ◽  
Breast Tumour ◽  
High Serum ◽  
Old Patients ◽  
Lower Quadrant ◽  
Outer Quadrant ◽  
Breast Malignancy ◽  
Malignant Breast ◽  
Average Serum

Background: Although for advanced tumour of breast have certain obvious physical characteristics, seldom is such physical finding seen in early malignant breast tumour. Keeping all these in mind, the present study aims at estimation of serum fucose which may help in early detection of breast malignancy.Methods: The present study was carried out over a period of one and a half year. A total of 68 patients were studied. Out of these 68 cases, 32 cases were having breast malignancy. After noting details history, through examination was done according to the proforma. Investigations were carried out as shown in proforma. Estimation of serum fucose was done in all these cases. Estimation of serum fucose was also done pre-operatively and in post-operative period.Results: It is evident from this that 70% of malignant lumps were seen in upper and outer quadrant of breast, 25% lumps in lower quadrant. It is obvious that as age advances average serum fucose level in breast cancer, starts decreasing. Thus younger patients have high Serum level as compared to old patients. Rise in serum level with the progression of stage of breast cancer. There was significant reduction observed in serum fucose level after surgery (p<0.0001).Conclusions:The estimation of serum fucose level can be used to screen cases of breast malignancy though neither as a strong arbiter, nor as a distinct diagnostic test. Its use is only as an ancillary investigation which may provide collaborative evidence only.  

scholarly journals Factors influencing efficacy of complete decongestive treatment in patients with breast cancer-linked arm lymphoedema

2021 ◽  
Vol 52 (2) ◽  
pp. 132-137
Author(s):  
Dragana Bojinović-Rodić ◽  
Samra Pjanić ◽  
Tamara Popović ◽  
Tatjana Nožica-Radulović
Keyword(s):  
Breast Cancer ◽  
Predictive Factors ◽  
Linear Regression Analysis ◽  
Breast Tumour ◽  
Multivariate Linear Regression Analysis ◽  
Malignant Breast ◽  
History Of ◽  
The Mean ◽  
Arm Lymphoedema ◽  
Mean Compliance

Background/Aim: The most recommended form of lymphoedema therapy is complete decongestive treatment (CDT). Efficacy of CDT in patients with arm lymphoedema related to malignant breast tumour has reported in many studies, but the predictive factors of outcome of this therapy have not been yet sufficiently investigated. The purpose of this research was to identify predictive factors of efficacy of CDT in patients with breast cancer-linked arm lymphoedema throughout the intensive phase of therapy. Methods: The prospective study included 51 patients with breast cancer-linked arm lymphoedema who were subjected to a 3-week program of CDT. Patients' clinical and demographic features, breast cancer treatment characteristics, lymphoedema and CDT characteristics were collected and assessed for their prognostic value. The influence of certain predictors on the degree of lymphoedema reduction was evaluated by multivariate linear regression analysis. Results: Mean age was 58.1 ± 8.0 (95 % CI: 55.8 - 60.3), median of BMI was 28.4 kg/m2 (95 % CI: 27.2 - 29.6). The average duration of lymphoedema was 36.5 ± 43.9 months (95 % CI: 24.1 - 48.8). The mean size of lymphoedema before CDT was 6.99 ± 5.36 %, and the mean degree of lymphoedema reduction was 63.7 ± 28.6 %. The mean compliance to bandages was 217.5 ± 97.8 hours (95 % CI: 190.0 - 245.0) and 7 (13.7 %) patients had a history of erysipelas of the ipsilateral arm. When observing each individual predictor, statistically most significant contribution showed the size of lymphoedema before the therapy (p < 0.001), then history of erysipelas (p < 0.01), and patients' age (p < 0.05). Conclusion: Size of lymphoedema before treatment is the most crucial prognostic factor of the efficacy of CDT in the patients with breast cancer-linked arm lymphoedema. The present study also identified history of erysipelas and patients age as independent predictors of the CDT efficacy.

scholarly journals Partial breast resection for multifocal lower quadrant breast tumour using virtual reality

2021 ◽  
Vol 14 (3) ◽  
pp. e241608
Author(s):  
Enora Laas ◽  
Mohamed El Beheiry ◽  
Jean-Baptiste Masson ◽  
Caroline Malhaire
Keyword(s):  
Breast Cancer ◽  
Virtual Reality ◽  
Breast Surgery ◽  
Breast Tumour ◽  
Oncoplastic Surgery ◽  
Breast Volume ◽  
Cancer Treatments ◽  
Lower Quadrant ◽  
Multiple Lesions ◽  
Multifocal Lesions

Oncoplastic surgery allows an increase in the number of indications for conservative breast cancer treatments. However, uncertainty as to whether it can be performed still exists in certain situations such as with multicentric or multifocal lesions, even when the breast volume can accommodate it. With the aid of a virtual reality software, DIVA, allowing the precise visualisation of tumours and breast volumes based entirely on the patient’s MRI, we report the ability to rapidly confirm and secure an indication for partial surgery of multiple lesions in a 31-year-old patient. With the described approach, the patient did not have to suffer significant disfigurement from cancerous breast surgery without compromising safety.

Factors Involved In the Plasminogen Activation System in Human Breast Tumours

1994 ◽  
Vol 71 (05) ◽  
pp. 684-691 ◽  
Author(s):  
László Damjanovich ◽  
Csaba Turzó ◽  
Róza Ádány
Keyword(s):  
Epithelial Cells ◽  
Connective Tissue ◽  
Plasminogen Activators ◽  
Breast Tumour ◽  
Plasminogen Activation ◽  
Malignant Tumours ◽  
Plasminogen Activation System ◽  
Activation System ◽  
Malignant Breast ◽  
Pai 1

SummaryThe plasminogen activation system is a delicately balanced assembly of enzymes which seems to have primary influence on tumour progression. The conversion of plasminogen into serine protease plasmin with fibrinolytic activity depends on the actual balance between plasminogen activators (urokinase type; u-PA and tissue type; t-PA) and their inhibitors (type 1 and 2 plasminogen activator inhibitors; PAI-1 and PAI-2). The purpose of this study was to determine the exact histological localization of all the major factors involved in plasminogen activation, and activation inhibition (plasmin system) in benign and malignant breast tumour samples. Our results show that factors of the plasmin system are present both in benign and malignant tumours. Cancer cells strongly labelled for both u-PA and t-PA, but epithelial cells of fibroadenoma samples were also stained for plasminogen activators at least as intensively as tumour cells in cancerous tissues. In fibroadenomas, all the epithelial cells were labelled for PAM. Staining became sporadic in malignant tumours, cells located at the periphery of tumour cell clusters regularly did not show reaction for PAI-1. In the benign tumour samples the perialveolar connective tissue stroma contained a lot of PAI-1 positive cells, showing characteristics of fibroblasts; but their number was strongly decreased in the stroma of malignant tumours. These findings indicate that the higher level of u-PA antigen, detected in malignant breast tumour samples by biochemical techniques, does not necessarily indicate increased u-PA production by tumour cells but it might be owing to the increased number of cells producing u-PA as well. In malignant tumours PAI-1 seems to be decreased in the frontage of malignant cell invasion; i.e. malignant cells at the host/tumour interface do not express PAI-1 in morphologically detectable quantity and in the peritumoural connective tissue the number of fibroblasts containing PAI-1 is also decreased.

scholarly journals Bone morphogenetic proteins, breast cancer, and bone metastases: striking the right balance

2017 ◽  
Vol 24 (10) ◽  
pp. R349-R366 ◽  
Author(s):  
Catherine Zabkiewicz ◽  
Jeyna Resaul ◽  
Rachel Hargest ◽  
Wen Guo Jiang ◽  
Lin Ye
Keyword(s):  
Breast Cancer ◽  
Cancer Progression ◽  
Bone Morphogenetic Proteins ◽  
Therapeutic Potential ◽  
Current Knowledge ◽  
Breast Tumour ◽  
Cellular Functions ◽  
Foetal Development ◽  
Key Factor ◽  
The Right

Bone morphogenetic proteins (BMPs) belong to the TGF-β super family, and are essential for the regulation of foetal development, tissue differentiation and homeostasis and a multitude of cellular functions. Naturally, this has led to the exploration of aberrance in this highly regulated system as a key factor in tumourigenesis. Originally identified for their role in osteogenesis and bone turnover, attention has been turned to the potential role of BMPs in tumour metastases to, and progression within, the bone niche. This is particularly pertinent to breast cancer, which commonly metastasises to bone, and in which studies have revealed aberrations of both BMP expression and signalling, which correlate clinically with breast cancer progression. Ultimately a BMP profile could provide new prognostic disease markers. As the evidence suggests a role for BMPs in regulating breast tumour cellular function, in particular interactions with tumour stroma and the bone metastatic microenvironment, there may be novel therapeutic potential in targeting BMP signalling in breast cancer. This review provides an update on the current knowledge of BMP abnormalities and their implication in the development and progression of breast cancer, particularly in the disease-specific bone metastasis.

scholarly journals The Secreted Protein C10orf118 Is a New Regulator of Hyaluronan Synthesis Involved in Tumour-Stroma Cross-Talk

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1105
Author(s):  
Ilaria Caon ◽  
Maria Luisa D’Angelo ◽  
Barbara Bartolini ◽  
Elena Caravà ◽  
Arianna Parnigoni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Patient Survival ◽  
Breast Tumour ◽  
Surrounding Area ◽  
Uncharacterized Protein ◽  
Stromal Fibroblasts ◽  
Tumour Cell Lines ◽  
Cell Niche ◽  
Hyaluronan Synthase 2 ◽  
Ncbi Blast

Interaction between cancer cells and their microenvironment is central in defining the fate of cancer development. Tumour cells secrete signals (cytokines, chemokines, growth factors) that modify the surrounding area, while the niche supplies structures and activities necessary for tumour maintenance and growth. Hyaluronan (HA) is a glycosaminoglycan that constitute cancer cell niche and is known to influence tumour functions such as proliferation, migration and neoangiogenesis. The knowledge of the factors regulating HA synthesis and size is crucial in understanding the mechanisms sustaining tumour development. Here we show that a yet uncharacterized protein secreted by breast tumour cell lines, named c10orf118 (accession number NM_018017 in NCBI/BLAST, and Q7z3E2 according to the Uniprot identifier), with a predicted length of 898 amino acids, can induce the secretion of HA by stromal fibroblasts through the up-regulation of the hyaluronan synthase 2 gene (HAS2). Intracellularly, this protein is localized in the Golgi apparatus with a possible role in vesicle maturation and transport. The expression of c10orf118 was verified in breast cancer patient specimens and was found to be associated with the presence of estrogen receptor that characterizes a good patient survival. We suggest c10orf118 as a new player that influences the HA amount in breast cancer microenvironment and is associated with low aggressiveness of cancer.

Sign in / Sign up

Export Citation Format

Share Document